Comparative Pharmacology
Head-to-head clinical analysis: EPANOVA versus TRAVASOL 2 75 IN DEXTROSE 20 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPANOVA versus TRAVASOL 2 75 IN DEXTROSE 20 IN PLASTIC CONTAINER.
EPANOVA vs TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Omega-3 fatty acids (EPA and DHA) reduce hepatic very low-density lipoprotein (VLDL) synthesis and increase triglyceride clearance from circulating VLDL particles through activation of lipoprotein lipase.
Provides exogenous amino acids and dextrose to meet caloric and protein requirements in patients who cannot tolerate enteral nutrition. Amino acids are used for protein synthesis and as substrates for gluconeogenesis and other metabolic pathways.
4 g orally once daily as 4 capsules of 1 g each with food.
Intravenous infusion: 500 mL to 1000 mL over 24 hours, titrated to provide 2.75% amino acids and 20% dextrose as part of parenteral nutrition. Rate based on glucose tolerance and metabolic needs.
None Documented
None Documented
Terminal elimination half-life approximately 89 hours (range 59–144 hr); allows weekly intramuscular dosing.
Amino acids: not applicable (endogenous metabolites). Dextrose: <15 minutes; clinical context: continuous infusion required to maintain glucose homeostasis.
Primarily hepatic metabolism via omega-oxidation and subsequent conjugation; renal excretion of metabolites: ~15% unchanged in urine; biliary/fecal elimination accounts for ~85% as metabolites.
Amino acids and dextrose are metabolized; excess nitrogen is excreted primarily as urea in urine. Dextrose is metabolized to CO2 and water. Biliary/fecal: negligible.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution